JP2007511486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511486A5 JP2007511486A5 JP2006538824A JP2006538824A JP2007511486A5 JP 2007511486 A5 JP2007511486 A5 JP 2007511486A5 JP 2006538824 A JP2006538824 A JP 2006538824A JP 2006538824 A JP2006538824 A JP 2006538824A JP 2007511486 A5 JP2007511486 A5 JP 2007511486A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- amino
- cyano
- pyrrolidine
- diethylpropion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical group CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 30
- 229960004890 diethylpropion Drugs 0.000 claims description 21
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 21
- 229960003562 phentermine Drugs 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 18
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 17
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 17
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 12
- 229960001243 orlistat Drugs 0.000 claims description 12
- 229960004425 sibutramine Drugs 0.000 claims description 10
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 10
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 3-hydroxy-1-adamantyl Chemical group 0.000 claims 21
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 18
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 18
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims 16
- 229960004597 dexfenfluramine Drugs 0.000 claims 16
- 239000000883 anti-obesity agent Substances 0.000 claims 15
- 229940125710 antiobesity agent Drugs 0.000 claims 15
- 230000036528 appetite Effects 0.000 claims 15
- 235000019789 appetite Nutrition 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 230000001105 regulatory effect Effects 0.000 claims 13
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 206010020772 Hypertension Diseases 0.000 claims 10
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 9
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 9
- 102000016267 Leptin Human genes 0.000 claims 9
- 108010092277 Leptin Proteins 0.000 claims 9
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 9
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 9
- 229940025084 amphetamine Drugs 0.000 claims 9
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 9
- 229960002837 benzphetamine Drugs 0.000 claims 9
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 9
- 229960002802 bromocriptine Drugs 0.000 claims 9
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 9
- 229960001058 bupropion Drugs 0.000 claims 9
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 9
- 229960002179 ephedrine Drugs 0.000 claims 9
- 229960001582 fenfluramine Drugs 0.000 claims 9
- 229960002464 fluoxetine Drugs 0.000 claims 9
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 9
- 229940039781 leptin Drugs 0.000 claims 9
- 229960000299 mazindol Drugs 0.000 claims 9
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 9
- 229960000395 phenylpropanolamine Drugs 0.000 claims 9
- 229960003908 pseudoephedrine Drugs 0.000 claims 9
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims 9
- 229960004394 topiramate Drugs 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- UIKDPMGTFQHKLC-UHFFFAOYSA-N 3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenylisoquinoline-6-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2C(=O)N(CC(C)C)C(CN)=C1C1=CC=CC=C1 UIKDPMGTFQHKLC-UHFFFAOYSA-N 0.000 claims 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 5
- 229960004937 saxagliptin Drugs 0.000 claims 5
- 108010033693 saxagliptin Proteins 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000003532 hypothyroidism Diseases 0.000 claims 3
- 230000002989 hypothyroidism Effects 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010042957 Systolic hypertension Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 229960000436 phendimetrazine Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 101000642226 Apomastus schlingeri U1-cyrtautoxin-As1b Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037469 Protein DEPP1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52056403P | 2003-11-17 | 2003-11-17 | |
| PCT/EP2004/012989 WO2005049088A2 (en) | 2003-11-17 | 2004-11-16 | Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511486A JP2007511486A (ja) | 2007-05-10 |
| JP2007511486A5 true JP2007511486A5 (enExample) | 2008-04-17 |
Family
ID=34619485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538824A Withdrawn JP2007511486A (ja) | 2003-11-17 | 2004-11-16 | Ｄｐｐ−ｉｖ阻害剤および抗肥満剤または食欲調節剤の組合せ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070149451A1 (enExample) |
| EP (1) | EP1687030A2 (enExample) |
| JP (1) | JP2007511486A (enExample) |
| KR (1) | KR20060109912A (enExample) |
| CN (1) | CN1901938A (enExample) |
| AU (2) | AU2004290896A1 (enExample) |
| BR (1) | BRPI0416627A (enExample) |
| CA (1) | CA2545514A1 (enExample) |
| MX (1) | MXPA06005596A (enExample) |
| RU (1) | RU2006121340A (enExample) |
| WO (1) | WO2005049088A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| BRPI0518241A (pt) * | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| EP2135603B1 (en) * | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
| JP2010508997A (ja) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
| HRP20130791T1 (en) | 2006-11-23 | 2013-09-30 | Sinoxa Pharma Gmbh | Pharmaceutical compositions for the treatment of capillary arteriopathy |
| AU2008210988B2 (en) * | 2007-02-01 | 2012-09-06 | Allocure, Inc. | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| CA2705708A1 (en) * | 2007-11-14 | 2009-05-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
| WO2009151714A2 (en) * | 2008-03-24 | 2009-12-17 | Palatin Technologies, Inc. | Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| ES2682644T3 (es) | 2009-06-05 | 2018-09-21 | Veroscience Llc | Combinación de agonistas de dopamina más secretagogos de insulina de primera fase para el tratamiento de trastornos metabólicos |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| CA2785822C (en) | 2010-01-11 | 2019-06-25 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| EP2651357B1 (en) | 2010-12-16 | 2020-04-01 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| JP5926363B2 (ja) * | 2012-02-22 | 2016-05-25 | 森永乳業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| JP5877560B2 (ja) * | 2012-03-09 | 2016-03-08 | 森永乳業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| KR20200035501A (ko) | 2012-06-06 | 2020-04-03 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| CN105920025B (zh) * | 2016-05-24 | 2018-11-06 | 华中科技大学同济医学院附属协和医院 | 托吡酯在治疗心肌梗死的药品中应用 |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| CN112055592A (zh) * | 2018-01-09 | 2020-12-08 | 吉拉毒蜥治疗公司 | 用于治疗代谢疾病的组合物和方法 |
| US11911445B2 (en) | 2018-01-23 | 2024-02-27 | Gila Therapeutics, Inc. | Peptide YY pharmaceutical formulations, compositions, and methods |
| MX2022002400A (es) | 2019-08-26 | 2022-06-08 | Period Pill Bv | Tratamiento de los sintomas inducidos por el ciclo menstrual. |
| JP2023508365A (ja) * | 2019-12-24 | 2023-03-02 | アードバーク・セラピューティクス・インコーポレイテッド | 多様な炎症性障害を処置または予防するための医薬組成物 |
| KR20250077661A (ko) | 2023-11-23 | 2025-06-02 | 재단법인 환동해산업연구원 | 항우울 및 항비만 효과를 가지는 해양생물자원 추출물 및 그 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| WO1998032458A1 (en) * | 1997-01-23 | 1998-07-30 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
| US6060458A (en) * | 1998-02-13 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use |
| JP2003520226A (ja) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| DE60226723D1 (de) * | 2001-03-27 | 2008-07-03 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| US7253172B2 (en) * | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| AU2003225916A1 (en) * | 2002-03-25 | 2003-10-13 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
-
2004
- 2004-11-11 US US10/579,580 patent/US20070149451A1/en not_active Abandoned
- 2004-11-16 MX MXPA06005596A patent/MXPA06005596A/es not_active Application Discontinuation
- 2004-11-16 KR KR1020067009505A patent/KR20060109912A/ko not_active Withdrawn
- 2004-11-16 JP JP2006538824A patent/JP2007511486A/ja not_active Withdrawn
- 2004-11-16 CA CA002545514A patent/CA2545514A1/en not_active Abandoned
- 2004-11-16 CN CNA200480040087XA patent/CN1901938A/zh active Pending
- 2004-11-16 BR BRPI0416627-2A patent/BRPI0416627A/pt not_active IP Right Cessation
- 2004-11-16 EP EP04797931A patent/EP1687030A2/en not_active Withdrawn
- 2004-11-16 AU AU2004290896A patent/AU2004290896A1/en not_active Abandoned
- 2004-11-16 RU RU2006121340/15A patent/RU2006121340A/ru unknown
- 2004-11-16 WO PCT/EP2004/012989 patent/WO2005049088A2/en not_active Ceased
-
2009
- 2009-04-09 AU AU2009201408A patent/AU2009201408A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511486A5 (enExample) | ||
| RU2006121340A (ru) | Комбинация ингибитора dpp-iv и агента от ожирения или агента контроля аппетита | |
| JP2007511487A5 (enExample) | ||
| RU2004110726A (ru) | Применение оксинтомодулина, способ и фармацевтическая композиция для профилактики или лечения избыточной массы тела, способ снижения массы тела | |
| AU2008267058C1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| JP2008515905A5 (enExample) | ||
| JP2008110964A5 (enExample) | ||
| WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| BR0311397A (pt) | Combinação de inibidor de dpp iv e um composto cardiovascular | |
| JP2023076632A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| JP2005523263A5 (enExample) | ||
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2004508399A5 (enExample) | ||
| JP2004514654A5 (enExample) | ||
| JP2009518415A5 (enExample) | ||
| JP2002501890A (ja) | 光学的に純粋な（＋）−ビュープロピオンの薬学的使用 | |
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| JP2007517885A5 (enExample) | ||
| JP2011528670A (ja) | 高血圧と代謝症候群の治療に用いられる医薬組成物及びその使用 | |
| RU2002127006A (ru) | Новое применение (r)-(-)-2-[5-(4-фторофенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей | |
| WO2005082884A3 (en) | 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease | |
| JP2003504404A (ja) | 抗虚血薬 | |
| JP2007511577A5 (enExample) |